This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.

Know when to use Earnouts to reduce risk, break a negotiation deadlock and get it done.

Get the strategies and insights to create a realistic term sheet that everyone can agree to.

A vast majority of businesses contract suppliers to provide goods and services to supplement their internal resources.

Working capital can be difficult to understand and is one of the most conflicting issues in M&A negotiations and valuation.

This all-purpose due diligence checklist contains a list of all the standard documents any buyer or partner might want to see.
.

The Life Sciences due diligence checklist covers unique characteristics applicable to your industry, which buyers or partners may want to examine.

Oncology venture funding, IPOs and partnerships have been exceptionally high in deal volume and values. Cancer continues to be the leading therapeutic area in the number and size of early deals, and the oncology pipeline continues to be a rich source of both follow-on agents as well as first-in-class programs.

If cybersecurity is not on the top of your company's list of initiatives for 2021, then it should be, and even if it is, you may not be doing enough.

In this whitepaper, learn what is artificial intelligence and how is it being applied to drug discovery, and much more.

This whitepaper provides a strategic perspective coupled with actionable tips to help guide you through the essential steps that will help maximize your chance of achieving success in biopharma partnering.

In this whitepaper, Linda Pullan provides licensing negotiations insights from a biotech business development perspective.